New insight into CCN3 interactions - Nuclear CCN3 : fact or fantasy? by unknown
BioMed CentralCell Communication and Signaling
ssOpen AcceResearch
New insight into CCN3 interactions - Nuclear CCN3 : fact or 
fantasy?
Bernard Perbal*
Address: Laboratoire d'Oncologie Virale et Moléculaire, UFR de Biochimie, Université Paris 7-D.Diderot, 75005, Paris, France
Email: Bernard Perbal* - perbal@ccr.jussieu.fr
* Corresponding author    
Abstract
The identification of potential partners for CCN3(NOV) sheds new light on the biological activity
of this signaling protein. In particular, the physical interaction of CCN3 with the IL33 cytokine
combined with previous data indicating that CCN3 expression was regulated by TNFalpha and IL1
cytokines, point to CCN3 as a potent player in a variety of inflammatory responses, including
neurodegenerative disease, and arthritis. Nuclear proteins that are involved in the regulation of
RNA processing and chromatin remodeling were also found to interact with CCN3. These
observations reinforce the concept that routing of CCN3 to the cell nucleus where it acts as a
transcription regulator, might constitute a key element in the balance between the anti- and pro-
proliferative activities of CCN3 proteins.
Background
Cellular biological processes are governed by several inter-
connected signaling pathways that allow fine tuning of
proliferation, growth arrest, differentiation, and death.
Central to this integrated control is a hierachy of regula-
tory circuitry that likely requires the interplay of multi-
protein complexes. Multimolecular complexes are known
to provide flexibility and subtle integrated responses to a
variety of paracrine or autocrine signals that may be syn-
ergistic and antagonist.
In the past decade, a new family of signaling proteins,
known as CCN proteins, has emerged [1,2]. These
secreted matricellular proteins are believed to play key
roles in several fundamental biological processes, among
which cell proliferation, differentiation and apoptosis
have been the most studied [3]. Their involvement in oste-
ogenesis, angiogenesis, regeneration, fibrosis and cancer
development is now well documented, and we have pre-
viously proposed [1,4] that the CCN proteins might act as
scaffolding or adaptor proteins that would permit the
interconnection between independent signaling pathways
that is required for balanced biological processes.
In spite of the increasing amount of interest devoted to
CCN proteins, very little is known regarding their mode of
action. This is probably due to the fascinating multimod-
ular organisation of the CCN proteins with a high cystein
content and a well-known tendency to aggregate, that
make it difficult to obtain large amounts of pure protein
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demonstrating detection of CCN RNAs and proteins in
various organs, increased or decreased expression of CCN
proteins in normal and pathological conditions, associa-
tion of CCN expression with differentiation or prolifera-
tive status in given tissues, but very few have addressed key
questions such as to the precise functions of CCN pro-
teins, their mechanisms of action, and whether they are
genuine signaling molecules or co-factors.
Very elegant work published by the groups of L. Lau and
K. Lyons [5,6] has identified defects resulting from knock
out of CCN1 and CCN2, thereby shedding light on the
critical functions of these two proteins in osteogenesis and
angiogenesis. Despite the considerable progress that was
brought by these reports the mode of action of CCN1 and
CCN2 remains elusive. Several publications have reported
the identification of proteins that physically interact with
CCN proteins [3]. The use of full length recombinant pro-
teins or variants lacking specific structural domains did
not permit, as yet, to assign biochemical function(s) com-
mon to the CCN proteins.
In an attempt to identify partners of the CCN proteins that
might provide clues in the search for CCN proteins bio-
chemical functions, we had previously used the yeast 2
hybrid strategy [7,8]. The results that were obtained sug-
gested that CCN3 interacted with several different types of
proteins and raised the possibility that in addition to part-
ners localized at the cell membrane or in the extracellular
matrix, the CCN3 protein might interact with the tran-
scription machinery in the nucleus of cells.
We now report on the analysis of an additional set of
clones that were positive in the two hybrid screening that
identify potential CCN3 partners suggesting other signal-
ing pathways in which CCN3 might be acting. This data
highlights the wide range of interactions in which CCN3
is involved, and reinforces the idea that nuclear CCN3 is a
putative regulator of transcription.
Methods
Two hybrid system screening
Conditions for screening the two hybrid system libraries
have been described previously [7,8]. Positive clones were
restreaked twice on selective medium deprived of histi-
dine and containing 25 mM 3-amino-1,2,3,4 triazole
(3AT), before checking interactions with the β-galactosi-
dase assay. Recombinant plasmids encoding the proteins
interacting with CCN3 were purified from 4 ml of yeast
grown overnight in minimal medium. Cells were centri-
fuged in microcentrifuge tubes and resuspended in 100 μl
of lysis buffer (2% Triton X100, 1% sodium dodecyl sul-
fate (SDS), 100 mM NaCl, 10 mM Tris/HCl, pH 8.0, 1 mM
EDTA, pH 7.5), 100 μl of sterile glass beads, and 100 μl of
a phenol/chloroform/isoamyl alcohol mixture (49.5/
49.5/1). After two minutes of vortexing, the mixture was
centrifuged for 20 minutes at 25°C and the upper phase
used as a source of DNA.
A series of clones that had not been analyzed in the previ-
ous studies, were expanded, and each individual clone
was streaked three consecutive times on plates containing
selective medium. DNA purified from each positive clone
was used to transform E. Coli HB101. Transformed bacte-
ria auxotrophic for the leucine marker and resistant to
ampicillin, were expected to contain plasmid encoding a
potential partner of CCN3. The plasmid DNAs were puri-
fied on Quiaquick columns. DNA sequencing was per-
formed by Genomex (Grenoble) and the sequences were
analyzed with the BLAST program (National Center for
Biology Information).
Transformation
Electrocompetent cells were prepared by seeding one litre
of LB medium with 10 ml of an overnight culture of the
appropriate bacterial strain. The cells were grown with
shaking at 250 rpm at 37°C until the culture reached an
optical density of 0.7 and they were then collected by cen-
trifugation at 4000 g in a prechilled GS3 Sorvall rotor for
15 minutes. The bacterial pellet was resuspended in one
litre of ice cold sterile 10% glycerol and the suspension
was centrifuged at 4000 g in the GS3 Sorvall rotor for 15
minutes at 4°C. The pellet was then resuspended in 0.5
litre of ice cold sterile 10% glycerol and centrifuged again
at 4000 g for 15 minutes at 4°C. The pellet was resus-
pended in 20 ml of ice cold sterile 10% glycerol, and cen-
trifuged again. The final pellet was resuspended in 2 ml of
ice cold sterile 10% glycerol and the resulting preparation
of electrocompetent cells was distributed in 100 μl aliq-
uots and frozen at -80°C. The competence of the bacterial
preparations was checked by performing a transformation
and counting the colonies obtained with a known
amount of pUC18 DNA. The ligation of vectors and
inserts to be cloned was usually performed for 18 hours at
12°C in 50 μl reaction samples containing 10 nM ends of
each DNA fragment and 1 μl of a high concentration T4
DNA ligase (New England Biolabs, Beverley, Massachu-
setts, USA; 400 U/μl). For transformation, ligation mix-
tures were mixed with 0.5 ml of electrocompetent cells in
electroporation cuvettes (Biorad, Marnes La Coquette,
France) on ice. Electroporation was performed with Bio-
rad Gene pulser (capacitance, 25 μF; resistance, 300
Ohms; at 1.8 KV). Electroporated bacteria were resus-
pended in 1 ml of chilled LB medium, incubated for one
hour with agitation (250 rpm) at 37°C, and spread on to
12% agar plates containing 100 μg/ml ampicillin.Page 2 of 8
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For the expression of the GST fusion proteins, BL21 bacte-
ria (Escherichia coli BF- ompT hsdS(rB- mB-) dcm+ Tetr gal
(DE3) endA Hte) were used. HB101 bacteria (F- supE44
ara14 galK2 lacY1 leuB6 thi-1 (gpt-proA)62 rpsL20 (Strr)
xyl-5 mtl-1 recA13 (mcrC-mrr) HsdS 20 (r- m-)) were
used to recover, from transformed yeast, the plasmid DNA
encoding the GAL4TA domain fused to the target protein
selected in the two hybrid screening. The cloning and
amplification of the other plasmids were performed in
DH5 (F'phi80dlacZ delta(lacZYA-argF)U169 deoR recA1
endA1 hsdR17 (rk-, m k+) phoA supE44 lambda-thi-1
gyrA96 relA1/F' proAB+ lacIqZdeltaM15 Tn10(tetr))
DNA preparation
The preparation of recombinant DNA was performed
with Qiagen kits. After performing the optional washing
of the columns, the recombinant plasmid DNA from the
minipreparations was usually eluted with 50 μl of sterile
distilled water. For midipreparations, the final DNA pellet
was resuspended in 300 μl of sterile distilled water.
Production and purification of GST fusion proteins
A 20 ml sample of an overnight culture of recombinant
bacteria grown in LB culture medium containing 100 μg/
ml ampicillin was used to seed one litre of ampicillin LB
medium. The culture was incubated at 37°C with agita-
tion at 250 rpm until an optical density of 0.6 was
reached. At that time, IPTG was added to a final concen-
tration of 0.1 mM to induce the production of the GST
fusion protein, for 90 minutes at 37°C with agitation.
Bacteria were collected after 10 minutes of centrifugation
at 4000 × g in a Sorvall GSA rotor at 4°C and resuspended
in 50 ml lysis buffer (10 mM Tris/HCl, pH 7.5, 100 mM
KCl, 1 mM EDTA, 5 mM dithiothreitol (DTT), and 0.5%
NP40), containing 100 mM phenylmethylsulfonyl fluo-
ride (PMSF), 10 mM TPCK (N-tosyl-L-phenylalanine
chloromethyl ketone), and 10 mM TLCK (N-p-tosyl-L-
lysine chloromethyl ketone). After adding 5 ml of lys-
ozyme solution (10 mg/ml in 25 mM Tris/HCl, pH 8.0)
the mixture was sonicated until the cells were completely
broken and centrifuged for 20 minutes at 5800 × g in a
Sorvall SS34 rotor to eliminate the cell debris. Each of the
two 25 ml fractions of supernatant was mixed with 1.5 ml
of GST sepharose beads (50% slurry in phosphate buff-
ered saline (PBS)), and incubated for one hour at 4°C on
a rotating wheel. The GST beads were centrifuged at low
speed in a table top centrifuge and washed five times with
6 ml binding buffer (20 mM Tris/HCl, pH 7.5, 100 mM
KCl, 2 mM CaCl2, 2 mM MgCl2, 5 mM DTT, and 0.5%
NP40), containing 100 mM PMSF, 10 mM TPCK, and 10
mM TLCK. Elution of the GST fusion protein was per-
formed by resuspension in 3 ml elution buffer (10 mM
reduced glutathione in 50 mM Tris/HCl, pH 8.0). After
one hour of agitation on a rotary wheel at 4°C, the mix-
ture was resuspended and the supernatant was collected.
The elution was repeated four times and the different frac-
tions kept separately. The quantity of the fusion protein
recovered was estimated by staining and comparison with
a bovine serum albumin calibrated standard after electro-
phoresis on a denaturing 12% polyacrylamide gel. The
protein fractions were lyophilised and kept at -80°C.
Before use, the lyophilised fractions were resuspended in
PBS, pH 7.5, and dialysed against the same buffer. Control
GST protein expressed by the PGEX4T1 vector alone was
produced, purified, stored, and used under the same con-
ditions.
In vitro transcription/translation
The templates for in vitro transcription/translation were
prepared as follows: 0.5 μl of each minipreparation DNA
plasmid was mixed with 10 μl buffer, 4.8 μl MgCl2, 10 μl
DMSO, and 62.2 μl water, as described above. The mix-
ture was boiled for five minutes and chilled on ice before
the addition of 7.5 μl of water, 2.0 μl of 10 mM dNTPs,
and 0.5 μl of Taq polymerase. The preparations were then
incubated for 35 cycles at 95°C for one minute, 60°C for
one minute, and 72°C for one minute. The in vitro tran-
scription/translation of PCR amplified templates was per-
formed with the TNT lysate reaction mix (Promega,
Charbonniéres, France), as recommended by the supplier,
with the following modifications: PCR products were
extracted once with 200 μl of a 24/1 mixture of chloro-
form and isoamyl alcohol, and precipitated by the addi-
tion of 15 μl 3 M sodium acetate and 500 μl of pre-chilled
(-20°C) absolute ethanol. After 10 minutes of incubation
in a dry ice/ethanol bath, the DNA precipitate was col-
lected by a 10 minute centrifugation at 12 000 g in a
microcentrifuge, washed once with 70% chilled ethanol,
and dried by speedvac centrifugation at medium temper-
ature. The DNA precipitate was resuspended in 6 μl of
sterile distilled water and mixed with 25 μl of the TNT
reticulocyte extract, 2 μl of the TNT reaction buffer, 1 μl of
T7 RNA polymerase, 1 μl of 1 mM amino acid mixture
deprived of methionine, 1 μl of RNAsin ribonuclease
inhibitor, and 4 μl of [35S] methionine (37 TBq/mmol, 10
mCi/ml). The mixture was incubated for 1.5 hours at
30°C; the in vitro proteins were analysed by electrophore-
sis on a 15% polyacrylamide gel and visualised by autora-
diography.
Primers
T7AD: 5'-TAA TAC GAC TCA CTA TAG GGA GAC CAC
CAC ATG GAT GAT GTA TAT AAC TAT CTA TTC-3'
4ADREV2: 5'-CAG TGA GCG CGC GTA ATA CGA CTC
ACT ATA-3'
After synthesis, the oligonucleotides were deprotected by
overnight incubation at 55°C, dried in 100 μl fractionsPage 3 of 8
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of TE (10 mM Tris/HCl, pH 8.0, 1 mM EDTA) before load-
ing on to 1 ml sephadex G25 columns previously pre-
pared in disposable plastic syringes. The flow through
contained the purified oligonucleotides.
Results
The analysis of 93 clones that showed various levels of
positivity in the two hybrid screening, identified several
new types of potential partners in addition to those that
we previously described [7,8]. These potential partners
included PAGP2, EF1alpha, SO4A1, Calmyrin,
LGALS3BP, IL33, SNRPA and HMGA1.
To check that the candidate clones encoded proteins that
could physically interact with CCN3 outside of the yeast
nucleus, the plasmids encoding the potential targets were
purified after transformation of HB101 bacteria and PCR
amplified before being used for in vitro transcription/
translation (see materials and methods). The [35S]
labelled proteins synthesised from the PCR amplified
templates were used to run GST pull down assays. Binding
of in vitro labelled proteins to GST-CCN3 sepharose
beads was revealed after SDS-PAGE analysis of the incuba-
tion mixtures.
The variety of proteins detected in this screen fit into the
known and postulated biological properties assigned thus
far to CCN3. Examination of the literature on these poten-
tial partners has revealed new insights into the possible
roles of CCN3 in signaling processes associated with
inflammation, and has reinforced the idea that nuclear
CCN3 variants are likely involved in the regulation of
transcription. The properties of these new partners are
briefly detailed below.
Membrane, transport, and recycling events
PGAP2 is a Golgi/ER-resident membrane protein that is
involved in the processing of glycosylphosphatidylinosi-
tol-anchored proteins (GPI-Aps) that is required for their
stable expression at the cell surface [9]. The potential
interaction of CCN3 with PGAP2 might provide clues for
the post translational processing of CCN3 and its trans-
port through the cell membrane.
The SO4A1 membrane protein is encoded by the
SLCO4A1gene [10]. It is a member of the homo sapiens
solute carrier organic anion transporter family. Also
known as OATP4A1, it mediates the Na(+)-independent
transport of organic anions such as thyroid hormones T3
(triiodo-L-thyronine), T4 (thyroxine) and rT3, and of
estrone-3-sulfate and taurocholate. The interaction of
CCN3 with SO4A1 would be in the same vein as previous
observations that reported the CCN3-mediated ion trans-
port [11].
Calmyrin is also known as calcium and integrin binding
protein(CIB1) [12]. Interaction of CCN3 with this EF-
hand calcium-binding protein [13,14] is in agreement
with the participation of CCN3 in calcium signaling and
with the physical interaction of CCN3 with integrins. The
calmyrin-CCN3 interaction might therefore be part of a
multiprotein complex allowing a direct cross talk between
regulatory pathways that control the intracellular calcium
concentration. Calmyrin is ubiquitously expressed. It is an
activating and inhibiting ligand of the inositol 1,4,5 tri-
phosphate receptor (InsPR). Calmyrin was reported to
activate InsPR gating in the absence of InsPR [15]. There-
fore, our observation raises the possibility that the effects
of CCN3 on calcium flux might involve an interactive
modulation of the calmyrin-induced gating. Considering
that brain is a major site of expression for CCN3 and that
calmyrin was detected in difuse and senile plaques, the
physical interaction of CCN3 and calmyrin and resulting
effects on calcium signaling, might also be of significance
in the pathogenesis of Alzheimer's disease.
The EF1 alpha translation elongation factor was identified
as a possible partner for several different types of proteins
that were assayed in the two hybrid system and interac-
tions with EF1alpha have often been considered as the
result of a technical artifact that constitute a drawback of
the selective procedure. However, it now well established
that EF1alpha is involved in proteasome-directed proteol-
ysis and is essential for ubiquitin-degration of certain pro-
teins [16]. Inasmuch as CCN3 is subject to post-
translational proteasome degradation (Bleau et al., sub-
mited for publication), the identification of EF1 as one of
its potential partners is highly relevant. It is interesting to
point out that EF1alpha was recently shown to be a poten-
tial oncogene overexpressed in ovarian and breast cancer
[17,18] and to play non canonical functions in cytoskele-
tal remodeling and apoptosis [19].
Inflammation
LGALS3BP (also known as 90 K, and MAC2 protein) is a
90 Kda secreted protein binds the human macrophage-
associated lectin (LGALS3:Lectin galactoside-binding sol-
uble 3) [20,21]. It contains a N-terminal region that
shows 45% identity with the extracellular part of the mac-
rophage scavenger receptor (MSR1). The 90 K protein is
present in the extracellular matrix of several tissues, as
well as in biological fluids. Also known as Mac2-binding
protein (M2BP, the former name of galectine 3 is Mac-2)
it was also shown to interact with several other extracellu-
lar proteins such as collagens, fibronectin, and nidogen
[20-23]. In this context, the binding of CCN3 to MAC2 is
in line with the interaction of CCN3 with collagen IV. On
a physiological standpoint, the interaction of CCN3 and
MAC2 is also supported by homotypic cell aggregation
induced by galectin binding and integrin-mediated cellPage 4 of 8
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increased in several cancers. In agreement with a possible
connection with CCN3 and inflammation (see below),
the production of MAC2 that is trigered by oncogenic
transformation and viral infection results in host immune
system response via IL2 and induction of other cytokines.
IL 33 is an interleukin-1(IL1)-like cytokine that signals via
the IL-1-receptor-related ST2. The ST2 receptor which was
an orphan member of the IL-1 family for about 15 years
was known as a negative regulator of Toll-like receptor-IL-
1 receptor signaling. IL 33 is the specific ligand for ST2
[24,25]. The biological effects of IL33 that are mediated by
the ST2 receptor include activation of NFkappaB and MAP
kinases, and production of T helper type 2-associated
cytokines [26]. Increased ST2 levels in the cerebrospinal
fluid (CSF) were associated to the inflammatory reaction
in the central nervous system after subarachnoid hemor-
rhage (SAH) [27]. Therefore, binding of CCN3 to IL33
might participate in the regulation of IL33 biological
activity in the context of inflammation.
Transcriptional events
Nuclear proteins were also identified as potential partners
of CCN3. The high mobility group A (HMGA) proteins
are non-histone chromosomal proteins implicated in the
organization of chromatin structure [28]. They participate
in the assembly of multi-protein complexes on the pro-
moter of several inducible genes, and are considered as
architectural transcription factors playing key roles in the
stereospecificity of transcription. The increased expression
of HMGA1 has been associated to both 3T3-L1 adipocytic
differentiation, and malignant cells proliferation. Further-
more rearrangements of HMGA genes has been detected
in human begnin tumors of mesenchymal origin and has
been correlated with highly malignant phenotype in sev-
eral human tumors [29-34]. Several of these biological
properties are shared by CCN3 whose expression was
reported to be increased in malignant tumors, to interfere
with adipocitic differentiation, and to be involved in the
tumorigenic phenotype of CML.
The small nuclear ribonucleoprotein polypeptide A
(SNRPA) is one of the three specific proteins found in the
U1 snRNP which is the most abundant U snRNP, that are
involved in pre-mRNA splicing. It is worth noting that
sera from patients with Systemic lupus erythematosus
(SLE), and diseases of connective tissue, in which abnor-
mal levels of CCN proteins have been reported, often con-
tain antibodies against sn-RNA associated proteins. SLE is
a chronic, remitting, relapsing, inflammatory disorder of
connective tissue. It is characterized by involvement of the
skin, joints, kidneys, and serosal membranes. An associa-
tion between chondrodysplasia punctata and maternal
SLE was also reported [35].
Discussion
In this study we identified new potential partners for
CCN3 that can be categorized into two main types of pro-
teins: those involved in the metabolic modification and
transport of CCN3 and those that point to CCN3 as a fac-
tor involved in external and intracellular signaling. Here
we highlight the potential roles for CCN3 in inflamma-
tory processes and transcriptional events. In particular, we
present data that argue for truncated forms of CCN pro-
teins as mediators of as yet unappreciated nuclear proc-
esses.
Inflammatory processes
Among the new potential partners of CCN3 that were
uncovered in this study, IL33 stands as a particularly inter-
esting one. Indeed, the possibility that IL33 signaling
functions are modulated through its interaction with
CCN3 is in line with previous observations that associated
CCN proteins to inflammation. For example, CCN6
(wisp3) was identified as a marker for inflammatory
breast cancer [36] and recent studies indicated that expres-
sion of ccn6 RNA was considerably increased in Rheuma-
toid arthritis (RA) and to lesser extent in osteoarthritis
(OA) [37]. Stimulation of RA fibroblast-like synoviocytes
(FLS) with interleukin 1 or tumor necrosis factor-a,
resulted in a significant increase of WISP3 mRNA. These
cytokines also increased WISP3 mRNA in OA FLS, but the
maximal level in stimulated OA FLS was less than
medium-treated RA FLS.
Recent studies revealed induced CCN2 expression in OA,
and suggested that CCN2 was involved in inflammatory
response and repair process of articular cartilage during
arthritis [38]. Both ccn2 and ccn1 expression was repressed
upon Tumor necrosis alpha (TNF-α) stimulation, and
both mRNA species were uniformly induced by trans-
forming growth factor (TGF)-β and dexamethasone [39].
In the case of MAV-induced nephroblastomas which rep-
resent a unique model of Wilms' tumor [40], we observed
that viral infection of tissue targets induced a dramatic
inflammation of the cortical region of the kidneys. This
inflammation occurred concomitant with an elevated
expression of CCN3 in the blastemal cells [Cherel et al.
Manuscript in preparation].
On the other hand, CCN3 was induced both at the protein
and the RNA level, by TNFalpha and IL1 in melanocytes
[M. Fukunaga et al. Submited for publication].
Considering the possibility that CCN3 is interacting with
IL33 and is induced by other inflammatory cytokines such
as IL1 and the pleiotropic TNF-α, one can predict its
involvement in inflammatory responses in tissues if it is
detected. For example, a role for CCN3 in OA and RA canPage 5 of 8
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lage and bone [[1], Bessette et al. Submited for publica-
tion].
In the same vein, the interaction of CCN3 with IL33 com-
bined with the high level of CCN3 expression in the brain,
makes it highly probable that CCN3 would be involved in
inflammatory responses in the nervous system. We had
previously reported that CCN3 expression was detected in
astrocytes and that the dorsal root ganglia is a major site
for CCN3 expression [41-44]. Myelinated fibers that
extend from the cell bodies contained in the dorsal root
ganglia constitute the dorsal funiculus (dorsal columns).
Upon selective dorsal rhizotomy, a surgical procedure per-
formed to reduce leg muscle stiffness and spasticity in
children who have cerebral palsy, CCN3 expression was
increased in dorsal funiculus [[45], Unpublished data].
Considering i) that CCN3 is involved in healing and tis-
sue repair, ii) the expression pattern of CCN3 in the nerv-
ous system, and iii) the connections of CCN3 with
cytokines, makes it a good candidate for playing a role in
the inflammatory response associated with neurodegener-
ative processes. Several animal models are being used to
test the potential role of CCN3 in flammatory diseases,
sclerosis and neurodegenerescence: the MRL-Lpr/Lpr mice
that are considered to have an autoimmune disease simi-
lar to human Lupus and the SOD mice that carry a
mutated transgene of CuZn superoxide dismutase gene
SOD1 which has been associated with amyotrophic lat-
eral sclerosis [46,47].
Nuclear processes
That CCN3 interacts with proteins involved in the trans-
port and processing of secreted proteins was not surpris-
ing. It was neither surprising that CCN3 interacted with
receptors at the cell surface and other proteins localized in
the extracellular matrix. However, the interaction of
CCN3 with rpb7, a subunit of RNA polymerase that is
found in the nucleus was unexpected and not fully
accepted, until we could demonstrate that the nuclear
CCN3 proteins can act as trans-repressor of transcription
in cultured cells [48]. However, since our attempts to
identify specific DNA binding sites for CCN3 did not
allow us to confirm a direct binding of CCN3 on target
DNA sequences, we have proposed that CCN3 might act
as a co-factor in the multiprotein complexes that govern
regulation of transcription.
In support for a role of CCN3 in the regulation of tran-
scription, we had previously reported that the expression
of an amino truncated CCN3 protein identified in tumor
cells was inducing chicken embryo fibroblast prolifera-
tion and transformation. Since our recent results estab-
lished that CCN3 proteins deprived of signal peptide were
routed to the nucleus where they inhibited transcription,
one can propose that the oncogenic potential of the
amino-truncated CCN3 was resulting from the downregu-
lated expression of antiproliferative or tumor-suppressor
genes, among which is CCN3 itself.
The identification of two other nuclear factors as potential
partners of CCN3 reinforce the idea that nuclear CCN3
proteins are acting as transcriptional regulators. The func-
tions of these factors strongly suggests that CCN3 might
participate in chromatin remodeling that takes place dur-
ing transcription. In addition to the involvement of
HMGA in chromatin structure, rpb7 is believed to partici-
pate in the cross talk with regulatory factors during tran-
scription, and SNRPA plays a critical role for the
maturation of newly synthesized transcripts.
Truncated forms of CCN as transcriptional mediators
The physical interaction of CCN3 with several proteins
which are part of the transcriptosome might account for
the detection of nuclear variants in pathological situations
leading to a higher proliferation rate, such as blastemal
hyperplasia induced by MAV, or in normal situations such
as myoblasts in which high levels of a 32 kDa amino trun-
cated CCN3 was detected. Our previous results [49] indi-
cated that retroviral-induced expression of a CCN3
protein lacking the IGFBP domain was inducing cell pro-
liferation and transformation. We also reported that a 32
kDa CCN3 protein, lacking the two first domains of
CCN3, was produced in the supernatant of CCN3-produc-
ing cultured cells [50]. It would therefore be of interest to
establish whether the production of amino-truncated
CCN3 outside of the cell is by any mean related to the
detection of truncated CCN3 variants inside the cell.
The lack of reagents allowing a precise caracterisation of
the CCN3 proteins detected in immunocytochemistry has
hampered the identification of truncated variants in tis-
sues or various origins. The antibodies that were have
developed and which specifically recognize the individual
structural domains of CCN3 [Lazar et al. Manuscript in
preparation] should prove helpful in this task.
Interestingly, the expression of truncated nuclear CCN3
proteins is correlated to the metastatic potential of
melanoma tumor cells (Rodolfo M. personal communica-
tion). We had previously reported that detection of CCN3
in primary Ewing tumors was associated with a higher risk
of developing metastasis [51] It will be interesting to
check whether truncated CCN3 proteins were produced in
these samples.
New evidence is now accumulating to support the concept
that the production of nuclear CCN3 proteins is associ-
ated with a higher, or at least disregulated proliferationPage 6 of 8
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duction of stable truncated CCN3 protein in the superna-
tant of cultured cells and in biological fluids such as
cerebrospinal fluid and serum, is by any mean related to
the detection of nuclear CCN3 variants. It is also worth
noting that large amounts of truncated CCN3 proteins are
detected in some tissues such as brain [43] and in the cyto-
plasm of highly proliferative cells [52].
The situation that we described for CCN3 has been
reported for other secretory proteins and there are several
precedents for secreted cytokines being internalized and
routed to the nucleus, either as a whole, or after post tran-
scritional modifications (see review by N. Planque CCS
submited). Recent data identified full length CCN3 pro-
tein in the nucleus of tumor cells, therefore raising the
possibilty that not only truncated forms would be routed
to another subcellular compartment, but that in some
cases, secretory processes might be altered and lead to the
accumulation of CCN3 in the cytoplasm or in the nucleus.
Whether the full length CCN3 protein also plays a role in
the regulation of transcription remains to be determined.
Should this activity be confirmed, the CCN3 protein
would definitely acquire the status of « moonlighting pro-
tein », as suggested previously [53].
Even though the nuclear localisation of cytokines and
other secretory factors has been widely documented over
the past decade, the concept is not yet unanimously recog-
nized because it is not in agreeement with dogmas of cel-
lular biology. Most significant progress arose from
controversial discoveries such as reverse transcription,
splicing, and autocatalytic activty of RNAs in the past. We
are confident that nuclear routing of secretory proteins
will be fully accepted in the near future and that there will
be no doubt that the presence of nuclear CCN3 proteins
in the nucleus is not a fantasy, but a true fact.
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